Susta-Med 300mg/ml 10ml Vial by Bioniche Pharma

Usage

1. Before drawing, visually inspect the vial under good lighting — confirm the oil is clear, particulate-free, and that the lot number on the vial matches the HPLC batch record provided.
2. Disinfect the rubber septum with an alcohol swab and allow it to dry fully before needle insertion to eliminate surface contamination.
3. Use a larger-gauge needle (21G) to draw the oil from the vial, then swap to a finer injection needle (23G–25G) to minimise injection-site trauma during administration.
4. Administer intramuscularly into a large muscle group (glute, vastus lateralis) using standard aseptic technique; rotate injection sites across the cycle to avoid localised tissue fatigue.
5. Anchor injection days to a fixed weekly schedule — twice-weekly intervals of 3–4 days maintain the ester-overlap structure that the pharmacokinetic profile is designed to deliver.
6. Log each injection date, volume, and site; cross-reference with mid-cycle bloodwork at week 4–6 to replace assumption-based dosing decisions with instrument-verified data.

Warnings

Frequently asked questions

Is it true that four-ester testosterone blends cause more water retention than single-ester testosterone enanthate at the same weekly dose?

This is a myth. Water retention during testosterone administration is driven by estradiol levels produced through aromatisation, which correlates with total weekly testosterone dose — not ester count or blend composition. At equivalent weekly milligram exposure, Susta-Med 300mg/ml produces comparable estradiol conversion to testosterone enanthate. Managing aromatase inhibitor dose based on bloodwork, not the number of esters, is the evidence-aligned approach.

Do multi-ester testosterone compounds suppress natural testosterone production faster than single-ester versions?

No — this is a pharmacological myth. HPG-axis suppression rate is governed by total circulating androgen concentration and the speed at which serum testosterone rises post-injection, not ester architecture. The propionate fraction in Susta-Med does elevate serum testosterone earlier than a single decanoate-only injection, but suppression depth at steady state reflects weekly dose, not blend complexity.

Is the claim that you can start PCT immediately after the last injection of a four-ester blend accurate?

No. This myth arises from confusion between the shortest and longest ester fractions in the blend. Because Susta-Med contains decanoate — the slowest-clearing ester — a clearance window of approximately 14–18 days after the final injection is required before SERM-based PCT can generate meaningful LH and FSH response. Anchoring PCT start to the decanoate half-life, not the propionate fraction, is the pharmacokinetically correct approach.

How should Susta-Med 300mg/ml be stored after the vial has been opened for the first time?

After first puncture, store the vial at room temperature (15–25°C), away from direct light and heat sources. Refrigeration is not required and can increase oil viscosity, making draws more difficult. Use a fresh sterile needle for each draw to preserve septum integrity. Bioniche Pharma's bromobutyl rubber stopper is designed for multi-dose access; discard the vial if any visible particulate matter or cloudiness develops.

Can Susta-Med 300mg/ml be drawn with an insulin syringe for low-dose protocols?

Yes, but with a practical note. At 300mg/ml, each 0.1ml graduation on a 1ml syringe corresponds to 30mg of testosterone ester blend, enabling doses of 60mg, 90mg, or 150mg with clean, readable graduation marks. For sub-60mg micro-doses, the draw volume falls below 0.2ml, which can introduce measurement imprecision on standard 1ml barrels; a 0.5ml insulin syringe with finer graduations is preferable for accuracy at those dose levels. (2) angle_used

Manufacturer

Bioniche Pharma's product portfolio across its injectable line is structured around a principle of formulation specificity: each product — including Susta-Med 300mg/ml — occupies a defined position within the range based on concentration, active ingredient, and intended clinical use case, rather than being a generic fill-and-label variation of a shared base formula. The portfolio architecture requires that every distinct formulation carries its own finished-product analytical record: ester-specific HPLC data and LAL endotoxin confirmation generated independently for that product's batch, not extrapolated from a related formulation's release documentation. Susta-Med's position within the Bioniche injectable portfolio reflects the manufacturer's documented commitment to concentration accuracy at 300mg/ml — a specification verified at the finished-product stage and traceable to the individual vial's lot number rather than inferred from API supplier certificates.